PTN earnings analysis
What we found in PTN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Palatin Technologies reported a strong Q3 FY2026 with substantial revenue growth, generating approximately $3.92 million compared to $0 in the prior year, driven by new collaboration agreements. The company recognized an EPS of -0.37, significantly lower than the estimated EPS of -0.82, reflecting improved operational efficiencies despite ongoing high net losses.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Strong Revenue Growth
- Revenue reached $3,920,675 in Q3 FY2026, a substantial increase from $0 in Q3 FY2025.
- Positive EPS Surprise
- Diluted EPS was reported at -0.37, beating the consensus estimate of -0.82.
- R&D Expense Reduction
- Research and development expenses decreased to $3,517,223 in Q3 FY2026 from $3,755,158 in Q3 FY2025.
- Cash Position Strengthened
- Cash and cash equivalents at $10,159,494 as of March 31, 2026, providing adequate liquidity for ongoing operations.
- Investment Income Boost
- Total other income for Q3 FY2026 improved to $148,007 compared to $1,757 a year ago.
- Increased Financing Activities
- Net cash provided by financing activities increased to $18,489,818 in 2026, compared to $7,710,261 in 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Dependence on Future Funding
- Continued operations depend on obtaining additional funding to support clinical trials and operations.
- Regulatory Approval Challenges
- Risks associated with delays in FDA and SEC approvals may hinder product commercialization timelines.
- Macroeconomic Headwinds
- Current economic conditions and uncertainties such as inflation and interest rates may impact operational efficiency.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.37
What they said about what is next.
Management remains optimistic about the upcoming quarters but has not provided specific numeric guidance in this filing.
The filing reads better than the one before it.
What came before.
- 10-Q · February 17, 2026
- Palatin Technologies reported substantial growth in revenue for Q2 FY2026, recognizing $116.036 million from collaboration and license revenue, a notable increase from $0 in the prior year period. Despite a significant…
- 10-Q · November 14, 2025
- Palatin Technologies reported a significant revenue increase in Q1 2026, totaling $8,847,550, compared to no revenue in the same quarter of the previous year. This quarter also saw an improvement in diluted EPS, which…
- 10-K · September 23, 2025
- Palatin Technologies has outlined an effort to develop first-in-class medicines primarily centered on the melanocortin receptor system, with a focus on obesity treatments. The fiscal year ended June 30, 2025 saw zero…
- 10-Q · May 14, 2025
- Palatin Technologies reported a significant decline in revenue for the nine months ended March 31, 2025, with zero product revenue compared to $4.14 million in the same period of the prior year following the sale of…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PTN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever